Breast cancer highlights from ESMO 2025 скачать в хорошем качестве

Breast cancer highlights from ESMO 2025

Dr Elisa Agostinetto joins us in Berlin to share her perspectives on the latest breast cancer data presented at ESMO 2025. Dr Agostinetto reviews data from the following studies: monarchE: Primary overall survival results of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer. Johnston S.R, et al. Abstract LBA13, ESMO 2025 DESTINY-Breast05: Trastuzumab deruxtecan vs trastuzumab emtansine in patients with high-risk HER2+ primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis. Geyer C.E, et al. Abstract LBA1, ESMO 2025 DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs SOC for high-risk HER2+ early breast cancer. Harbeck N, et al. Abstract 291O, ESMO 2025 ASCENT-03: Primary results from a randomised phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer who are unable to receive PD-(L)1 inhibitors. Cortés J.C, et al. Abstract LBA20, ESMO 2025 TROPION-Breast02: 1st line datopotamab deruxtecan vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Dent R.A, et al. Abstract LBA21, ESMO 2025 How will these data impact clinical practice? Watch to find out! See more updates from ESMO 2025 on our website: https://cor2ed.com/n-connect/programm... Looking for similar breast cancer programmes? Update From ASCO 2025: https://cor2ed.com/n-connect/programm... Managing ADC toxicities in HER2+ metastatic breast cancer - Spotlight on nausea and vomiting: https://cor2ed.com/breast-cancer-conn... Follow BREAST CONNECT on: X – https://x.com/BreastCaConnect LinkedIn –   / breastcancerconnect   This video is developed by cor2ed.com Published October 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.